China vs US: The New War Over Cancer Drugs and Biotech Supremacy | The Morning Brief Decode
The Morning BriefShow Notes
China challenged America's dominance in manufacturing, technology and artificial intelligence. Now, it is threatening another American stronghold: the pharmaceutical industry. Chinese biotech companies are developing breakthrough drugs faster and cheaper than their American counterparts. One Chinese cancer drug, ivonescimab, is emerging as a potential challenger to Keytruda, Merck's $31-billion blockbuster. Meanwhile, Western pharmaceutical giants are striking multibillion-dollar licensing deals with Chinese innovators. But Washington is worried. Could America's growing dependence on Chinese biotechnology become a national security threat? And could India benefit from this escalating rivalry? In this episode of The Morning Brief Decode, Anirban Chowdhury speaks to The Economic Times' pharma editor Vikas Dandekar about China's biotech revolution, the battle for the future of medicine, the US response and India's opportunity to become a bigger player in global drug innovation. See omnystudio.com/listener for privacy information.
More from The Morning Brief
India’s smartphone market is heading into Diwali on a sour note. Shipments fell sharply in the July–September quarter, with the sub-₹20,000 segment hit hardest. A global memory-chip crunch is raising costs, pushing up prices and forcing buyers to delay upgrades, settle for fewer features or choose refurbished phones. But does this slump signal a wider squeeze on household spending, or is it a supply shock tied to the race to build AI data centres? We examine what falling shipments reveal about affordability, consumption and India’s mobile growth, with Counterpoint Research’s Tarun Pathak and Bank of Baroda chief economist Madan Sabnavis. See omnystudio.com/listener for privacy information.
What if you didn’t need a tech team, or any code, to build software? In this episode of Corner Office Conversation, Anirban Chowdhury sits down with Mukund Jha, Founder and CEO of Emergent, the AI platform where anyone with an idea can build a real, hosted, working app. A former Google engineer, Mukund also co-founded Dunzo, the unicorn that became a verb in India...and then folded. He shares hard-won Dunzo lessons on growth versus endurance, focus and unit economics, and why second-mover advantage matters in AI. Emergent says 18 million apps have been built on it. Mukund believes anyone could soon build any software without code. See omnystudio.com/listener for privacy information.
The Supreme Court has set aside Yes Bank’s 2020 write-down of ₹8,415 crore in AT1 bonds. Anirban Chowdhury speaks to Sugata Ghosh of The Economic Times about how AT1 bonds work, why the Court ruled against the write-down, what the judgment means for investors and regulators, and how the case compares with Switzerland’s Credit Suisse AT1 dispute See omnystudio.com/listener for privacy information.
AI agents undergoing tests accessed Indian organisations’ live systems and read confidential business records and personal data. The companies did not detect these intrusions; AI developers disclosed them after internal reviews. What happens when an AI agent exceeds its instructions, and who should bear the consequences? Anirban Chowdhury speaks to lawyer Pavan Duggal and Prof NK Goyal of CMAI about the warning from the Indian Computer Emergency Response Team, the challenges of assigning liability and the safeguards businesses need. From disclosure requirements to protecting sensitive information, this episode examines whether India’s laws and corporate defences can keep pace with autonomous AI. See omnystudio.com/listener for privacy information.
As AI becomes more powerful, who gets to shape its direction—and share its benefits? ET’s tech editor Surabhi Agarwal speaks to Google DeepMind’s Chief AI Readiness Officer, Lila Ibrahim, about the tension between rapid development and responsible deployment. They discuss India’s place in the global AI race, the role of teachers in AI-enabled classrooms, and research that could help farmers grow more resilient crops. Ibrahim also reflects on responsibility inside DeepMind, the work around AlphaFold, and the everyday ways she uses AI as a parent. A conversation about preparing people and institutions for a technology already changing their lives. See omnystudio.com/listener for privacy information.